Health Care Services

Kingmed Diagnostics

Kingmed Diagnostics released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 1.492 B (forecast CNY 1.592 B), actual EPS CNY -0.2 (forecast CNY 0.15)

Kingmed Diagnostics released FY2025 annual earnings on April 24 After-Market BJT, actual revenue CNY 6.03 B (forecast CNY 6.13 B), actual EPS CNY -0.37 (forecast CNY -0.0691)

Kingmed Diagnostics released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 1.351 B (forecast CNY 1.562 B), actual EPS CNY 0.09 (forecast CNY 0.25)

Kingmed Diagnostics to Release FY2026 Q1 Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 1.562 B, EPS CNY 0.25

Kingmed Diagnostics to Release FY2025 Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 6.13 B, EPS CNY -0.0691

Kingmed Diagnostics released FY2025 9 Months earnings on October 29 During-Market (BJT), actual revenue CNY 4.538 B, actual EPS CNY -0.1677

Kingmed Diagnostics released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 1.541 B (forecast CNY 1.712 B), actual EPS CNY 0.0112 (forecast CNY 0.12)

Kingmed Diagnostics to release FY2025 Q3 earnings on October 30 During-Market BJT, forecast revenue CNY 1.712 B, EPS CNY 0.12

Kingmed Diagnostics released FY2025 Semi-Annual Earnings on August 22 After-Market BJT, with actual revenue of CNY 2.997 B and EPS of CNY -0.18

Kingmed Diagnostics released FY2025 Q2 earnings on August 22 After-Market BJT, actual revenue CNY 1.53 B (forecast CNY 1.612 B), actual EPS CNY -0.1189 (forecast CNY -0.07)

Kingmed Diagnostics to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Kingmed Diagnostics Issues First-Ever Loss Forecast

Kingmed Medical Expected to Report Loss in First Half of 2025

Kingchuang Kaiyuan Plans to Reduce Holdings in Kingmed 1%

Kylin Medical Responds to Stock Decline and Accounts Receivable Issues

Kingmed Diagnostics Registers 55 New Software Copyrights

Kingmed Reports First Loss, Receivables Issues Evident

Yuan Wei of Guojin Securities Issues Buy Rating Report on Kingmed

Guojin Securities Gives Buy Rating to KingMed Diagnostics

Kingmed Diagnostics Reports Q1 2025 Loss Following 2024 Annual Report

603882

Kingmed Diagnostics announced that its revenue for the third quarter was 1.541 billion yuan, a year-on-year decrease of 11.32%; net profit was 5.1973 million yuan, a year-on-year increase of 24.08%. Revenue for the first three quarters was 4.538 billion yuan, a year-on-year decrease of 19.23%; net profit recorded a loss of 79.6095 million yuan, a year-on-year decrease of 184.84%

Zhitong

Kingmed Diagnostics: Third quarter net profit of 5.1973 million yuan, a year-on-year increase of 24.08%

On October 23rd, a reporter learned from Kingmed Diagnostics that the cancer pathology gene large model DeepGEM has recently been deployed at the company. Relying on this large model, the company will collaborate with Tencent and the First Affiliated Hospital of Guangzhou Medical University to jointly develop a multimodal large model for pathological genes, allowing accurate, timely, and accessible gene mutation prediction technologies to benefit more cancer patients. (Science and Technology Daily)

Wallstreetcn

The cancer pathology gene large model DeepGEM is implemented

Kingmed Diagnostics stated on the interactive platform that the company, relying on its comprehensive platforms and technologies such as serology, fluorescence PCR, and first and second generation sequencing at the infection testing center, has launched testing for chikungunya virus, which can accurately identify pathogens and assist in precise clinical diagnosis

Kingmed Diagnostics: Has launched testing for Chikungunya virus

Kingmed Diagnostics announced that it expects to achieve a net profit attributable to shareholders of the listed company of -65 million yuan to -95 million yuan for the first half of 2025, a year-on-year turnaround from profit to loss. It is expected that the net profit attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be -78 million yuan to -110 million yuan for the first half of 2025

Kingmed Diagnostics: Expected net profit loss of RMB 65 million to RMB 95 million in the first half of 2025

According to the Zhitong Finance APP, Kingmed Diagnostics announced that its shareholder Guochuang Kaiyuan intends to reduce its holdings of the company's shares by no more than 4.6326 million shares through centralized bidding, accounting for 1.00% of the company's total share capital

Kingmed Diagnostics shareholder Guochuang Kaiyuan plans to reduce its holdings by no more than 1%

300006

300511

688331

09995

300204

The cell immunotherapy sector saw a short-term surge, with Staidson BioPharm rising over 10%, followed by XUERONG, RemeGen, Kingmed Diagnostics, Lummy, and Heyuan Bio

Lummy

XUERONG

RemeGen

REMEGEN

Staidson BioPharm

OBiO Tech

The cellular immunotherapy sector has seen a short-term surge, with Staidson BioPharm rising over 10%

300253

000710

603716

300676

300244

The AI healthcare sector experienced a surge, with Berry Genomics hitting the limit up, while Thalys, BGI Genomics, Dian Diagnostics, Winning Health, Kingmed Diagnostics, and Huakang Clean also rose significantly

Winning Health

Berry Genomics

Thalys

BGI Genomics

Dian Diagnostics

Huakang Clean

The AI medical sector experiences a surge, with Berry Genomics hitting the limit up

002044

The medical services sector continues to rise, with BGI Genomics up over 10%, Dian Diagnostics and Berry Genomics up over 7%, and Kingmed Diagnostics and Meinian Onehealth following suit

Meinian Onehealth

The medical services sector continues to rise, with BGI Genomics up over 10%

Kingmed Diagnostics announced that its controlling shareholder, Liang Yaoming, pledged 7 million shares, accounting for 9.43% of his holdings and 1.51% of the company's total share capital. After the pledge, Liang Yaoming and his concerted parties have cumulatively pledged 38.13 million shares, accounting for 23.11% of his holdings and 8.23% of the company's total share capital

Kingmed Diagnostics: Controlling shareholder pledges 7 million shares

Kingmed Diagnostics(603882.SH)